DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 2 OpenAI's ChatGPT - 2 Daphne Koller - 2 MacArthur - 2 Elon Musk - 1 Musk - 1 Nicolai Tangen - 1 OpenAI - 1
Top related locs:
Davos Switzerland today's silico
Top related orgs:
Service - 2 Google - 2 Microsoft - 2 Norges Bank - 1 Business - 1 Wall Street - 1 Reddit - 1 Stanford - 1

Search resuls for: "Daphne Koller"


5 mentions found


☆ Elon Musk says AI will be smarter than humans in 2 years
  + stars: | 2024-04-09 | by ( Aaron Mok | ) www.businessinsider.com   time to read: +4 min
In March, Musk wrote on X that AI will be smarter than "all humans combined" by 2029. (Coincidentally, Musk says OpenAI has poached some of Tesla's AI engineers.) Related stories"We're seeing a lot of the best talents going into AI," Musk says in the interview. Last year's constraint, Musk says, was the dwindling supply of chips needed to power AI training efforts. AdvertisementMusk expects to encounter these challenges in making Grok, an AI chatbot backed by his startup xAI, smarter than its rivals.
Persons: —, Elon Musk, Musk, Nicolai Tangen, OpenAI, Grok, OpenAI's ChatGPT, it's, Daphne Koller, MacArthur, " Koller Organizations: Service, Norges Bank, Business, Google, Microsoft, Wall Street, Reddit, Stanford
☆ Don't worry — the machines won't be as smart as humans for a long time, because they've still got a lot to learn
  + stars: | 2024-01-20 | by ( Hasan Chowdhury | ) www.businessinsider.com   time to read: +6 min
Much of today's most popular AI models, such as OpenAI's GPT-4, are trained on what's publicly available on the internet. It's worth noting that AI models exist today that are pretty effective at generating images, but these are text-to-image models, like Midjourney and Stable Diffusion. Koller also sees issues with today's LLMs. This isn't the first time doubts have been raised about the capacity of today's AI models. Steve Jennings/Getty Images for TechCrunchThis is not to say today's LLMs are useless.
Persons: —, OpenAI's ChatGPT, Bill Gates, Daphne Koller, MacArthur, Koller, Neilson Barnard, chatbots, Yann LeCun, –, today's LLMs, LLMs, that's, Kai, Fu Lee, Steve Jennings Organizations: Economic, Service, Big Tech titans, Google, Microsoft, Getty, Meta Locations: Davos, Switzerland, today's, silico
☆ The next big thing in Big Tech career path is an AI-based 'bilingual' job skillset
  + stars: | 2023-04-02 | by ( Eric Rosenbaum | ) www.cnbc.com   time to read: +8 min
Microsoft unveiled new versions of its Bing internet-search engine and Edge browser powered by the newest technology from ChatGPT maker OpenAI. But the biggest one of all may be next, he says, through the combination of artificial intelligence and branches of science involved in medicine. But the opportunity won't translate into achievement without a new form of collaboration between the classic big tech talent and the medical field. One of her portfolio companies, Insitro, was founded by Stanford AI researcher Daphne Koller (Koller co-founder edtech company Coursera). "There is lots of exciting big talent opportunities coming from big tech and big cap pharma," she said.
☆ Why biotech CEOs are growing more cautious about going public — and what they're waiting for
  + stars: | 2023-01-30 | by ( Andrew Dunn | Yeji Jesse Lee | ) www.businessinsider.com   time to read: +6 min
Biotech-startup CEOs are taking more nuanced approaches to going public amid a downturn. SAN FRANCISCO — After record years of initial public offerings in 2020 and 2021, biotech leaders told Insider that the "recipe" for going public no longer works. Most biotechs saw their valuations increase by between 20% and 50% after going public. Insider asked five startup CEOs about how they approach going public and their perspectives on the biotech-IPO market for 2023. But going public doesn't carry an importance of validation for herself or the field of biotech companies specializing in AI, she said.
☆ The recipe biotech startups use to go public is being thrown out. 5 startups CEOs reveal how they're changing their focus.
  + stars: | 2023-01-26 | by ( Andrew Dunn | Yeji Jesse Lee | ) www.businessinsider.com   time to read: +6 min
Biotech-startup CEOs are taking more nuanced approaches to going public amid a downturn. SAN FRANCISCO — After record years of initial public offerings in 2020 and 2021, biotech leaders told Insider that the "recipe" for going public no longer works. Most biotechs saw their valuations increase by between 20% and 50% after going public. Insider asked five startup CEOs about how they approach going public and their perspectives on the biotech-IPO market for 2023. But going public doesn't carry an importance of validation for herself or the field of biotech companies specializing in AI, she said.
0 next >>
Total: 5